Choose your Location
  • MBE illumigene Malaria Milestone Infographic

    2 March 2017
    MBE Malaria Infographic

    #illumigene #Malaria #Infographic #MeridianBioscience


    illumigene Malaria by Meridian Bioscience

    2 March 2017

    illumigene Malaria by Meridian Bioscience

    The diagnosis of Malaria (Plasmodium sp.) has remained a critical piece in both the control of this vector borne disease and clinical case management of patients affected by malaria.

    Traditional methods of diagnosis have long remained entrenched as the status quo. Methods such as microscopy and rapid diagnostic tests (RDTs) have continued to be used in both non-endemic and endemic settings. Molecular detection methods have emerged, but have so far fallen short of widespread adoption due to a number of key factors: bulky, specialist capital equipment requirements, expense, highly-trained staff with expertise, cold storage of reagents, complex workflows & impractical field use.

    illumigene Malaria by Meridian Bioscience, in the space of 12 months has literally transformed molecular diagnosis offering an innovative choice of molecular diagnostic assays suited not only to non-endemic, Western European laboratories, handling imported malaria cases, but serving a crucial role in both the endemic regions of sub-Saharan Africa and the sub-microscopic, low parasitemia reservoirs of asymptomatic carriers - a known source of transmission. This latter group is key in the success or failure of any in-country elimination programme to achieve full eradication of malaria. An expert, namely, Professor Daouda Ndiaye, Dakar, Senegal has remarked in a Malaria World expert blog that “early data suggests it has the potential to become a new gold standard for molecular malaria diagnosis for case investigation, particularly in pre-elimination settings”. This new paradigm was formally recognized during the JIB-ACNBH (Journées Internationales de Biologie/Association des Colloques Nationaux des Biologistes 2016 Conference, Paris, France, where it received 1st prize in the Innovation category: emergency treatment and point-of-care testing.

    illumigene, thus far, in the hands of a multitude of parasitology experts across Europe, Middle East and Africa, has repeatedly demonstrated its accuracy, with a proven negative predictive value (NPV) of 100% and equally it's performance in reliably screening for positives in less than 1 hour, achieving high levels of sensitivity and unparalleled ease-of-use.

    During World Malaria Day, April 25, 2017, Dr Tom van Gool (Academic Medical Centre, Amsterdam, Netherlands) as part of a morning session on parasite diagnosis, will present ground breaking results from a multi-centric trial, following an evaluation of the illumigene Malaria assays. This scientific presentation will take place during ECCMID 2017 (The 27th European Congress of Clinical Microbiology and Infectious Diseases), hosted this year in Vienna, Austria; an event regarded by many as the leading flagship congress worldwide, for microbiologists and infectious disease specialists with a projected attendance of 15,000 participants and over 3,000 abstracts accepted as part of its broad scientific programme.


    "illumigene Malaria will establish itself as a milestone in Malaria diagnosis history, much like the cell counter-blood analyser has done following its introduction into the routine laboratory."

    "illumigene will set a new paradigm in reliably mitigating against false positives, thereby facilitating a far easier diagnosis."

    "In situations where ILG calls a positive result as a frontline screen ahead of a haemoscopy negative result for the same blood sample(s), then further investigations will be required to reconcile the result with the clinical picture. For this reason, the result can be considered esoteric with clinical expertise and laboratory input being required."

    Romualo Grande, MD
    UOC Microbiologia Clinica
    Sacco Ospedale, ITALY

    #illumigene #MeridianBioscience #Malaria

    Rick L. Eberly discusses the Bioline Mission, Product Strategy and Values

    7 January 2017

    Richard L. Eberly the President, Chief Commercial Officer of Meridian Bioscience, Inc. discusses the Bioline mission, product strategy and the corporate values Bioline follows.

    To watch our Values video,click here